Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. Bridel C, Beauverd Y, Samii K, Lalive PH Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e123. Epub 2015 Jun 18. PMID: 26140281. Abstract CommentRecommendBookmarkWatch